JPRN-jRCT2021260024 HRS-5346 Unmet-Need Clinical Development Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready landscape. This focused report examines JPRN-jRCT2021260024—A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and when Coadministered with Enlicitide Decanoate in Adults With Elevated Lipoprotein(a)—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.
MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.
Why JPRN-jRCT2021260024 is a hot trial to watch
Unmet-Need Clinical Development is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. JPRN-jRCT2021260024 is notable because it evaluates HRS-5346 in a Phase 2 design while - Percent Change from Baseline in Lp(a) at Week 8 (MK-7262 + enlicitide vs. placebo, MK-7262 monotherapy vs. placebo, MK-7262 + enlicitide vs. enlicitide monotherapy) - Percent Change from Baseline in LDL-C at Week 8 (MK-7262 + enlicitide vs. placebo, MK-7262 + enlicitide vs. MK-7262 monotherapy) - Number of Participants who Experience One or More Adverse Events (AEs) - Number of Participants Who Discontinue Study Intervention Due to an AE serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.
PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | JPRN-jRCT2021260024 |
| Official title | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and when Coadministered with Enlicitide Decanoate in Adults With Elevated Lipoprotein(a) |
| Phase / status | Phase 2 / 募集前 |
| Intervention | HRS-5346, Enlicitide chloride |
| Sponsor | MSD KK (Tokyo) |
| Collaborators | Not reported |
| Geography | Colombia, United States, Japan, Switzerland, Spain, Netherlands, Canada, Germany, Denmark |
| Enrollment | 750 |
| Primary endpoint | - Percent Change from Baseline in Lp(a) at Week 8 (MK-7262 + enlicitide vs. placebo, MK-7262 monotherapy vs. placebo, MK-7262 + enlicitide vs. enlicitide monotherapy) - Percent Change from Baseline in LDL-C at Week 8 (MK-7262 + enlicitide vs. placebo, MK-7262 + enlicitide vs. MK-7262 monotherapy) - Number of Participants who Experience One or More Adverse Events (AEs) - Number of Participants Who Discontinue Study Intervention Due to an AE |
| Endpoint time frame | Not reported |
| Primary completion / readout proxy | [object Object] |
Design and endpoint interpretation
The phase label is only the starting point. Allocation is Randomized, masking is Double, and the intervention model is Factorial Assignment. Planned enrollment of 750 participants across Colombia, United States, Japan, Switzerland, Spain, Netherlands, Canada, Germany, Denmark shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary: - Percent Change from Baseline in Lp(a) at Week 8 (MK-7262 + enlicitide vs. placebo, MK-7262 monotherapy vs. placebo, MK-7262 + enlicitide vs. enlicitide monotherapy) - Percent Change from Baseline in LDL-C at Week 8 (MK-7262 + enlicitide vs. placebo, MK-7262 + enlicitide vs. MK-7262 monotherapy) - Number of Participants who Experience One or More Adverse Events (AEs) - Number of Participants Who Discontinue Study Intervention Due to an AE
- Primary: -投与8週時におけるLp(a)のベースラインからの変化率（MK-7262＋enlicitide併用とプラセボ、MK-7262単独投与とプラセボ、MK-7262＋enlicitide併用とenlicitide単独投与の比較） -投与8週時におけるLDL-Cのベースラインからの変化率 （MK-7262＋enlicitide併用とプラセボ、MK-7262＋enlicitide併用とMK-7262単独投与の比較） -1件以上の有害事象を発現した治験参加者数 -有害事象により試験介入を中止した治験参加者数
- Secondary: -投与8週時におけるLDL-Cのベースラインからの変化率（enlicitide単独投与とプラセボの比較） -投与8週時におけるLDL-Cのベースラインからの変化率（MK-7262単独投与とプラセボの比較） -投与8週時におけるLp(a)のベースラインからの変化率（MK-7262＋enlicitide併用とMK-7262単独投与の比較） -投与8週時におけるLDL-Cのベースラインからの変化率（MK-7262＋enlicitide併用とenlicitide単独投与の比較） -投与8週時にLp(a) 125 nmol/L未満を達成した治験参加者の割合 -投与8週時にLp(a) 75 nmol/L未満を達成した治験参加者の割合 -投与12週時におけるLp(a)のベースラインからの変化率 -投与12週時におけるLDL-Cのベースラインからの変化率
- Secondary: - Percent Change from Baseline in LDL-C at Week 8 (enlicitide monotherapy vs. placebo) - Percent Change from Baseline in LDL-C at Week 8 (MK-7262 monotherapy vs. placebo) - Percent Change from Baseline in Lp(a) at Week 8 (MK-7262 + enlicitide vs. MK-7262 monotherapy) - Percent Change from Baseline in LDL-C at Week 8 (MK-7262 + enlicitide vs. enlicitide monotherapy) - Percentage of Participants with Lp(a) <125 nmol/L at Week 8 - Percentage of Participants with Lp(a) <75 nmol/L at Week 8 - Percent Change from Baseline in Lp(a) at Week 12 - Percent Change from Baseline in LDL-C at Week 12
Benchmark readouts in the surrounding field
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of RDX-002 on Postprandial Triglycerides in Patients Discontinuing the Glucagon-like Peptide-1 (GLP-1) Agonists, Semaglutide, or Tirzepatide for the Treatment of Obesity (Phase 2): Incremental Postprandial Triglycerides (TG)(Mean) = 43.81 percent change (Standard Deviation, 92.373); Incremental Postprandial Triglycerides (TG)(Mean) = -51.91 percent change (Standard Deviation, 72.293)
- A Phase II Study to Evaluate the Delay in Ovulation Following Oral Levonorgestrel Plus Meloxicam Compared to Placebo in Obese But Normal Menstruating Women (Phase 2): Interval From First Dose to Evidence of Ovulation.(Mean) = 2.67 Number of days (Standard Deviation, 1.53); Interval From First Dose to Evidence of Ovulation.(Mean) = 4.0 Number of days (Standard Deviation, 0)
- A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight (Phase 2): Percent Change From Baseline in Body Weight at Week 48(Least Squares Mean) = -0.4 percent change (Standard Error, 0.91); Percent Change From Baseline in Body Weight at Week 48(Least Squares Mean) = -9.4 percent change (Standard Error, 1.60)
These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.
Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset context: HRS-5346 (Phase 2; Lp(a)); Enlicitide chloride (NDA/BLA; PCSK9)
Company & Deal Intelligence context: MSD KK (Tokyo) — Japan — http://www.msd.co.jp
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Sequencing evidence: comparative data after the most relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.
Bottom line
JPRN-jRCT2021260024 is a focused lens on Unmet-Need Clinical Development development. Its value will be determined by whether HRS-5346 can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
